Navigation Links
Akela Pharma reports results for third quarter of fiscal 2007
Date:11/9/2007

ation of the Fentanyl TAIFUN(R) Phase II trial program and the development of our product candidates.

The consolidated net loss for the third quarter of 2007 was $8.6 million, or ($0.73) per share and $23.8 million or ($2.03) per share year-to-date, compared with a consolidated net income for the former Pharma segment of $12.0 million and $0.8 million, respectively.

The Company had cash and cash equivalents as of September 30, 2007 of $15.1 million. compared with $35.3 million as of December 31, 2006.

THE ISSUER HAS FILED A REGISTRATION STATEMENT (INCLUDING A PROSPECTUS) WITH THE SEC (FILE NO. 333-146684) FOR AN OFFERING OF ITS SECURITIES. BEFORE YOU INVEST, YOU SHOULD READ THE PROSPECTUS IN THAT REGISTRATION STATEMENT AND OTHER DOCUMENTS THE ISSUER HAS FILED WITH THE SEC FOR MORE COMPLETE INFORMATION ABOUT THE ISSUER AND THIS OFFERING. YOU MAY GET THESE DOCUMENTS FOR FREE BY VISITING EDGAR ON THE SEC WEB SITE AT http://WWW.SEC.GOV. ALTERNATIVELY, THE ISSUER, ANY UNDERWRITER OR ANY DEALER PARTICIPATING IN THE OFFERING WILL ARRANGE TO SEND YOU THE PROSPECTUS IF YOU REQUEST IT BY CONTACTING OPPENHEIMER AND CO. INC. AT 125 BROAD STREET, 16TH FLOOR, NEW YORK, NEW YORK 10004, ATTENTION: SYNDICATE DEPARTMENT, OR BY PHONE AT (212) 825 4341

About Akela Pharma Inc.

Akela Pharma is an integrated drug development company focused on developing therapies for the growing multi-billion dollar inhalation and pain markets. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, growth hormone deficiencies and controlled substance abuse deterrent formulations.

Akela's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "AKL" with 11.7 million shares outstanding.

This news release contains certain forwar
'/>"/>

SOURCE Akela Pharma Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
2. Akela Pharma Inc. Completes Share Consolidation
3. AKELA Pharma Inc. announces U.S. public offering and proposed listing
4. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
5. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
9. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... New York (PRWEB) March 28, 2015 ... ) involving devices manufactured by C.R. Bard, Inc. ... underway in U.S. District Court, Southern District of ... Grand, is serving on the Plaintiffs’ Steering Committee. ... the Court has granted certain defendants named in ...
(Date:3/28/2015)... Centurion Service Group will be hosting a live on-site ... their Las Vegas warehouse, located at 4606 Andrews St. Suite ... of equipment from hospitals and surgery centers from around the ... , Buyers will find items of all types including anesthesia, ... said Erik Tivin, CEO of Centurion. , Among the sale’s ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Early ... patients with Type V AC joint injuries, according to ... presented today at the American Orthopaedic Society for Sports ... returned to duty faster when surgery was not performed. ... with 7 receiving surgical treatment and 17 receiving non-surgical ...
(Date:3/28/2015)... March 28, 2015 Healthpointe’s otolaryngologists, medical ... and throat disorders, are now offering a wide ... issue which is characterized by the presence of phantom ... 5 people, tinnitus is a prevalent symptom that can ... it is non-fatal, tinnitus can impede a person’s quality ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Servpro ... , this week released a report about the link ... of asthma sufferers, and according to recent medical research, ... , According to the Environmental Protection Agency, people with ... reactions. Breathing in mold may trigger asthma attacks for ...
Breaking Medicine News(10 mins):Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3
... Benefit Susan G. Komen for the Cure; $6.3 Million Raised to ... ... and television,personalities, professional athletes and other celebrities are teaming up,with American Airlines this ... Airlines Celebrity Golf and Tennis Weekend,Oct. 4-7 at the Four Seasons Resort Aviara ...
... Congressman Chaka Fattah,(D- PA) responds to the ... "The numbers just don,t add up. This ... war, but he won,t support $35 million to ... health insurance is vital to their,well being. Today,s ...
... received a five year, $5 million renewal grant from ... to provide financial and career support for 39 doctoral ... pre-dissertation doctoral students. This grant seeks to address the ... workers by supporting future aging-focused faculty who will ...
... Oct. 3 Immucor, Inc. (Nasdaq:,BLUD), a global ... transfusion industry, today reported financial results for the,fiscal ... for the fiscal first quarter was a record ... same period last year. Of the $12.6 million ...
... faculty member Rachel Jones has been selected to be the ... 2007 Tribute to Nurses Award. , The New York Times ... of candidates nominated by patients and their families, students and ... in the Dec. 2 New York Times Magazine. , ...
... uses CT scans and is performed without anesthesia , , ... supports the effectiveness of an innovative form of colonoscopy ... a patient,s colon. , When it comes to ... colonoscopy" is just as effective as the traditional approach ...
Cached Medicine News:Health News:American Airlines 13th Annual Celebrity Golf and Tennis Weekend Will Raise Funds to Fight Breast Cancer 2Health News:American Airlines 13th Annual Celebrity Golf and Tennis Weekend Will Raise Funds to Fight Breast Cancer 3Health News:Hartford Foundation awards grant to address geriatric social work shortage 2Health News:Immucor Announces Record Fiscal First Quarter Revenues 2Health News:Immucor Announces Record Fiscal First Quarter Revenues 3Health News:Immucor Announces Record Fiscal First Quarter Revenues 4Health News:Immucor Announces Record Fiscal First Quarter Revenues 5Health News:Immucor Announces Record Fiscal First Quarter Revenues 6Health News:Immucor Announces Record Fiscal First Quarter Revenues 7Health News:Immucor Announces Record Fiscal First Quarter Revenues 8Health News:Rutgers College of Nursing faculty member Rachel Jones wins New York Times Nurse Award 2Health News:'Virtual' Colonoscopy an Effective Option: Study 2Health News:'Virtual' Colonoscopy an Effective Option: Study 3
(Date:3/27/2015)... 2015 XRpro Sciences, Inc., a provider ... development services which features high throughput transporter and ... financial results for the year ended December 31, ... of XRpro Sciences commented, "We have completed a ... stage to commercial stage in large part by ...
(Date:3/27/2015)... March 27, 2015 Report Details  ... leading ophthalmic drug companies  What does the ... ophthalmic industry ? Visiongain,s brand new report shows you ... prospects there. Our 242-page report provides 185 ... in the industry and the future market prospects. Our ...
(Date:3/27/2015)... , March 27, 2015 ... by Product (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation Catheter ... X-ray)) & Indication (AF, VT, WPW) - Global Forecasts ... is expected to reach around ~$4.73 Billion by 2019 ... period 2014 to 2019. Browse   ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
... Galleon Pharmaceuticals, a leader in the pharmaceutical treatment of ... has elected Thomas J. Dietz, Ph.D., as the company,s ... Holdings, LLC, a diversified financial-holdings and services company.   ... then CEO and a director of Pacific Growth Equities, ...
... Reportlinker.com announces that a new market ... Medical Imaging Markets: Contrast ... The application and versatility of ... in significance as the population ages and ...
Cached Medicine Technology:Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals 2Medical Imaging Markets: Contrast Agents 2Medical Imaging Markets: Contrast Agents 3Medical Imaging Markets: Contrast Agents 4Medical Imaging Markets: Contrast Agents 5Medical Imaging Markets: Contrast Agents 6
... The many benefits of fibre bronchoscopy: The ... by which all other fibre bronchoscopes are ... bronchoscopes from PENTAX, including the FB-19TV, FB-18V ... slim FB-10V and the pediatric FB-8V, offer ...
... many benefits of fibre bronchoscopy: The HF-compatible ... which all other fibre bronchoscopes are measured., ... from PENTAX, including the FB-19TV, FB-18V and ... FB-10V and the pediatric FB-8V, offer much ...
... benefits of fibre bronchoscopy: The HF-compatible V ... all other fibre bronchoscopes are measured., ... PENTAX, including the FB-19TV, FB-18V and FB-15V ... and the pediatric FB-8V, offer much better ...
... fiberoptic bronchoscopes offers a ... with a slim outside ... allows for improved suction ... cytology brushes. The scope ...
Medicine Products: